Drug Discovery

#Clinical specialities #Clinical trials #Drug discovery #Imaging #Lead discovery #Regulatory

Abivax treats first patient in COVID-19 clinical trial in France

The first patient has been treated in Abivax’s Phase IIa/III study of ABX464 in COVID-19 patients at the University Hospital Centre in Nice, France. The randomised, double-blind, placebo-controlled miR-AGE study investigates the effect of early treatment (at point of diagnosis) in 1,034 COVID-19 elderly or high-risk patients. The… Read More

#Covid-19 #News

#Automation / robotics #Biochemistry #Biologics / Biotechnology #Business #Cell therapy #Clinical trials #Drug discovery #High Content Screening #High throughput screening #Immunology / Virology & Vaccines #Oncology #Screening #Therapeutics

DDW summer issue now out

2 July 2020 From the race to the COVID-19 cure to the new manufacturing technologies that could be a game changer for stem cell therapies. With COVID-19 still a significant feature in the drug discovery landscape, this issue looks at the race to finding a cure – from… Read More

#News

#Cellular & Molecular biology #Clinical specialities #Clinical trials #Drug discovery #High throughput screening #Imaging #Target validation

EUSA Pharma receives FDA approval of phase III clinical trial for siltuximab

2 July 2020 Image: Nino Liverani The US Food & Drug Administration (FDA) has approved a randomised, double-blind, placebo-controlled phase III clinical trial protocol to evaluate the safety and efficacy of intravenous siltuximab. It will also evaluate the standard of care in hospitalised patients with COVID-19 associated Acute… Read More

#News

#Business #Clinical trials #Drug development #Drug discovery #Immunology / Virology & Vaccines #RNA

Symbiosis secures £1 million of growth finance from Allied Irish Bank

1 July 2020 Image: Micheile Henderson Symbiosis Pharmaceutical Services has secured £1million of finance from Allied Irish Bank (GB) to support its 2020 growth strategy. Symbiosis provides niche, sterile manufacturing services to global biotechnology and pharmaceutical company clients that are developing novel drug therapies and vaccines for use… Read More

#News

#Biologics / Biotechnology #Cell therapy #Clinical specialities #Clinical trials #Drug discovery #Gene therapy #Imaging #Lead discovery #Precision medicine #RNA

Clinical trial examines alpha-1-antitrypsin for severe COVID-19 infection

Clinician scientists at RCSI University of Medicine and Health Sciences, Ireland, have begun a clinical trial of a promising therapy for critically ill COVID-19 patients in intensive care. In a paper published in the American Journal of Respiratory and Critical Care Medicine, the team, led by RCSI Professors… Read More

#Covid-19 #News

#Academic #Analysis #Assay development optimisation & technology #Business #Cellular assays #Clinical specialities #Drug development #Drug discovery #Enabling technologies #Genomics #High Content Screening #High throughput screening #Imaging #Immunology #Lead discovery #Microfluidics #RNA #Screening #Stem cells #Therapeutics #Translational #Translational chemistry

MMR vaccination might protect children from COVID-19

Image: CDC A group of Lithuanian and Kurdish scientists have raised a hypothesis that the measles, mumps, and rubella (MMR) vaccine could protect children from COVID-19. The hypothesis is based on the discovered sequence similarity of the 30 amino acid residues between glycoproteins of SARS-CoV-2, measles and rubella… Read More

#Covid-19 #News

#Academic #AI / data analytics / healthtech / informatics #Assay development optimisation & technology #Biologics / Biotechnology #Business #Cellular assays #Chemical engineering #Chemistry #Drug development #Drug discovery #Drug targets #Enabling technologies #Gene editing #Genomics #High Content Screening #High throughput screening #Imaging #Medicinal chemistry #Microfluidics #Screening #Stem cells #Therapeutics #Translational #Translational chemistry

PharmEnable raises £1.8 million for drug discovery expansion

30 June 2020 Image: Lucas Vasques PharmEnable, has closed a £1.8 million seed financing to support its transition into a drug development company. The Cambridge, UK-based drug discovery company uses advanced medicinal chemistry and AI-enabled approaches to design the next generation of highly complex and specific drug candidate… Read More

#News

#Academic #AI / data analytics / healthtech / informatics #Assay development optimisation & technology #Business #Cellular assays #Clinical specialities #Drug development #Drug discovery #Enabling technologies #Gene editing #Genomics #High Content Screening #High throughput screening #Imaging #Immunology #Immunology / Virology & Vaccines #Lead discovery #Microbiology #Microfluidics #Molecular medicine #Nanomedicine / nanotechnology #Protein chemistry / Proteomics #Screening #Stem cells #System biology #Therapeutics #Translational #Translational chemistry

Engineers use ‘DNA origami’ to identify vaccine design rules

30 June 2020 Image: Glen Carrie In lab tests, virus-like DNA structures coated with viral proteins provoke a strong immune response in human B cells, by Ann Trafton, MIT News Office By folding DNA into a virus-like structure, MIT researchers have designed HIV-like particles that provoke a strong immune… Read More

#News

#Academic #AI / data analytics / healthtech / informatics #Assay development optimisation & technology #Business #Cellular assays #Drug development #Drug discovery #Enabling technologies #Gene editing #Genomics #High Content Screening #High throughput screening #Imaging #Lead discovery #Microfluidics #RNA #Screening #Stem cells #Therapeutics #Translational #Translational chemistry

Collaboration launches Autobahn Labs, novel early stage drug discovery incubator

29 June 2020 Image: Clay Banks Evotec, Samsara BioCapital, KCK have launched Autobahn Labs, a novel virtual incubator partnering with top academic and research institutions to catalyse early-stage drug discovery and development. Autobahn Labs also announced a first-in-kind strategic collaboration with UCLA Technology Development Group to identify and… Read More

#News

#Cell therapy #Drug development #Gene therapy #Toxicology

PARP inhibitor could be effective treatment for childhood neuroblastoma

29 June 2020 Image: National Cancer Institute A type of drug already used to treat breast and ovarian cancer, called a PARP inhibitor, may be useful in treating children with high-risk neuroblastoma, a childhood tumour with a low survival rate, a new study suggests. Neuroblastoma is a cancer… Read More

#News

#Biologics / Biotechnology #Biomarkers #Business #Clinical trials #Drug development #Drug discovery #Lead discovery #Oncology #RNA #Therapeutics #Translational #Translational chemistry

Major boost for AMR Centre as it receives share of Strength in Places Fund award

29 June 2020 Image: Mark Fletcher-Brown The AMR Centre has combined forces to attract investment to combat the global threat of antimicrobial resistance (AMR) resulting in a successful bid for a £114 million project supported by UK Research and Innovation (UKRI) The funding was secured by a North… Read More

#News

#Academic #Business #Cell therapy #Cellular assays #Drug development #Drug discovery #Enabling technologies #Genomics #High Content Screening #High throughput screening #Imaging #Microfluidics #Screening #Stem cells #Therapeutics #Translational #Translational chemistry

Leukaemia treatment mystery solved

26 June 2020 Image: National Cancer Institute A research team led by the University of Kent and Goethe-University Frankfurt am Main, has solved an almost 40-year old mystery in leukaemia therapy and the drug nelarabine. Acute lymphoblastic leukaemia (ALL) is the most common cancer in children. Read More

#News

#Academic #Biomarkers #Business #Clinical trials #Drug development #Drug discovery #Lead discovery #RNA #Target validation #Therapeutics

Liverpool scoops £18.6 million research grant to tackle infectious diseases

26 June 2020 Image: Conor Samuel A Liverpool School of Tropical Medicine-led consortium has received an £18.6 million grant from the UK Research and Innovation (UKRI) Strength in Places Fund (SIPF) to deliver a major project to tackle infectious diseases, including COVID-19. The funding award recognises Liverpool City… Read More

#News

#Clinical trials #Drug discovery #High Content Screening #High throughput screening #Imaging #Lead discovery #Stem cells #System biology

Imaging system produces human cellular morphological data for COVID-19 research

With the COVID-19 pandemic impacting millions around the globe, researchers are racing to develop a vaccine or drug treatment. In an effort to better understand the cellular responses to COVID-19, the digital biology company Recursion has publicly released the world’s largest imaging dataset portraying therapeutic compound effects from over 1,600 approved… Read More

#Covid-19 #News

#Academic #Analysis #Assay development optimisation & technology #Business #Cellular assays #Chemistry #Drug development #Drug discovery #Enabling technologies #Genomics #High Content Screening #High throughput screening #Imaging #Metabolomics #Microbiome #Microfluidics #Molecular medicine #Screening #Stem cells #Target validation #Therapeutics #Translational #Translational chemistry

Metabolon and DNA Genotek collaborate on microbiome sampling solution for metabolomics

25 June 2020 Metabolon and DNA Genotek have teamed up to create OMNImet-GUT, said to be the first device for in-home collection and ambient-temperature storage and shipping of faecal samples for metabolomics, to the research market. “For years, our customers from across biopharma, academia and… Read More

#News